Subscribe To
RCUS / Buy 3 Top Profitable Stocks Using Net Income Ratio
RCUS News
By Zacks Investment Research
August 7, 2023
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Misses Revenue Estimates
Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to more_horizontal
By Zacks Investment Research
May 9, 2023
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Tops Revenue Estimates
Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.09 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares more_horizontal
By Zacks Investment Research
February 28, 2023
Arcus Biosciences, Inc. (RCUS) Reports Q4 Loss, Tops Revenue Estimates
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 6.06% and 45.10%, respectively, for the quarter ended December 2022. Do the more_horizontal
By Zacks Investment Research
February 14, 2023
Buy 3 Top Profitable Stocks Using Net Income Ratio
Arcus Biosciences (RCUS), Suzano (SUZ), and Arch Resources (ARCH) has been selected as the top picks with a high net income ratio. more_horizontal
By Zacks Investment Research
January 12, 2023
Down -45.21% in 4 Weeks, Here's Why Arcus Biosciences, Inc. (RCUS) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Arcus Biosciences, Inc. (RCUS) as it is technically in oversold territory now. In addition to this more_horizontal
By Proactive Investors
December 20, 2022
Arcus Biosciences, Gilead Sciences shares fall as new lung cancer drug data fails to meet investor expectations
Arcus Biosciences Inc and Gilead Sciences Inc shares have both taken a tumble after the companies reported positive but not groundbreaking results fro more_horizontal
By Market Watch
December 20, 2022
Arcus Biosciences, Gilead shares are down after sharing data about new lung cancer drug
Shares of Arcus Biosciences Inc. RCUS, -1.23% were down 17.2% in premarket trading on Tuesday, the day after the company said the experimental treatme more_horizontal
By Investors Business Daily
November 28, 2022
Gilead's Cancer Program Notches Another Win, But It's Arcus Stock That Surges
Gilead and Arcus notched another win for their cancer program on Monday, pushing GILD stock briefly to a four-year high as RCUS stock gapped higher. T more_horizontal